AI-generated · cited to primary sources · not investment advice
Medtronic plc. (MDT) Apr 2026 Filing Analysis
What could break the thesis?
The risk remains high. Medtronic reports that hospitals, group purchasing organizations, and integrated delivery networks are increasing purchasing leverage, while Medicare, Medicaid, private insurers, and international tender programs are applying cost-containment measures. Fiscal 2026 cost of products sold rose to $12.721 billion from $11.632 billion, and the cost ratio increased, showing continued margin pressure. China represents approximately 6% of revenue and is exposed to volume-based procurement pricing. (1 intensifying)
“Cost of products sold as a percentage of net sales increased as compared to the prior fiscal year. The increase in cost of products sold as a percentage of net sales was primarily due to $185 million of increased tariffs and duties on imported goods and $84 million of asset write offs.”
See the full cited Risk analysis of Medtronic plc.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.